NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX): Assessing Valuation After New Phase 2 Bipolar I Mania Trial Launch
Neurocrine Biosciences (NBIX) just kicked off a randomized, double blind, placebo controlled Phase 2 trial of NBI-1117568 in adults with Bipolar I manic episodes, a meaningful pipeline step that helps explain recent investor interest.
See our latest analysis for Neurocrine Biosciences.
At around a 145 dollar share price, Neurocrine has delivered a solid 1 year total shareholder return of roughly 6 percent, with the recent Phase 2 update helping underpin steadily improving sentiment despite...